Translational Development Acquisition Corp Class A ordinary shares Logo
KYG9008W1050

Translational Development Acquisition Corp Class A ordinary shares

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Kaufen
  1
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Trident Acquisitions Corp. Files 10K/A

    NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Trident Acquisitions Corp. (the “Company”) filed a Form 10-K/A for the period ended March 31, 2021 on June 25, 2021 after receiving a second notice from Nasdaq (the “Second Nasdaq Notice”) on June 21, 2021. The Second Nasdaq Notice stated that, since the Company had not yet filed its Form 10-Q for the period ended March 31, 2021 (the “Form 10-Q Deficiency”), such deficiency serves as an additional basis for delisting the Company's securities. The Second Nasdaq Notice provided formal notification to the Company that the Panel will consider the Form 10-Q Deficiency at the hearing to be held in connection with the notice the Company received from Nasdaq on June 3, 2021, stating that the Company was not in compliance with Listing Rule IM-5101-2 (the “First Nasdaq Notice”). Today's filing of the Form 10-K/A allows the Company to imminently file the Form 10-Q, seeking to clear the delinquency.» Mehr auf globenewswire.com


  • Exclusive: Lottery.com CEO Says Company Plans To Be A 'Global Marketplace For All Types Of Games Of Chance'

    AutoLotto, Inc (Lottery.com) is set to go public via special purpose acquisition company (SPAC) with Trident Acquisitions Corp (NASDAQ: TDAC). The two companies entered into a definitive agreement for a merger on Feb. 22.» Mehr auf benzinga.com

Unternehmenszahlen

Im letzten Quartal hatte Translational Development Acquisition Corp Class A ordinary shares einen Umsatz von 0,00 und ein Nettoeinkommen von +1,37 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00-
Nettoeinkommen+1,37 Mio175.607,29%
EBITDA321,13k-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+193,02 Mio
Anzahl Aktien
21,91 Mio
52 Wochen-Hoch/Tief
+8,83 - +8,55
DividendenNein
Beta
1,87
KGV (PE Ratio)
+125,75
KGWV (PEG Ratio)
+0,35
KBV (PB Ratio)
29,89
KUV (PS Ratio)
0,00

Unternehmensprofil

Name
Translational Development Acquisition Corp Class A ordinary shares
CEO
Michael M. B. Hoffman
Mitarbeiter2
🍪

Parqet nutzt Cookies.Erfahre Mehr